Clinical Trial Update: Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy [Phase 2, Phase 3]

View source ↗

Summary

Update on a Phase 2/3 trial comparing Izalontamab Brengitecan with platinum-based chemotherapy for metastatic urothelial cancer that progressed after immunother…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• Izalontamab Brengitecan
• Platinum-based chemotherapy (platinum-based chemotherapy)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Urothelial Cancer | Phase 2, Phase 3 | Status: RECRUITING